Identifying NID2 as A Potential Drug Target and Biomarker for Various Diseases

Target Name: NID2

NCBI ID: G22795

NID2

Identifying NID2 as A Potential Drug Target and Biomarker for Various Diseases

NID2 (NID2_HUMAN), a novel gene expressed in the human placenta, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and infertility. NID2 is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of various diseases.

The NID2 gene was first identified in a comprehensive gene expression analysis of human placenta tissue using RNA sequencing technology. The RNA sequencing data revealed that the NID2 gene was expressed in all three placenta samples and was differentially expressed between the placenta and the other tissues of the human body.

To further investigate the functions of NID2 in the human body, a number of in vitro and in vivo studies were performed. These studies demonstrated that NID2 was involved in various physiological processes in the human body, including cell growth, apoptosis (programmed cell death), and inflammation.

One of the most significant findings from these studies was that NID2 was expressed in various types of cancer cells, including breast, ovarian, and colorectal cancer. This suggests that NID2 may be a useful target for cancer therapies that target RNA molecules involved in cancer growth and progression.

In addition to its role in cancer, NID2 was also shown to be involved in neurodegenerative disorders. Studies have shown that NID2 was expressed in the brains of individuals with Alzheimer's disease and other forms of neurodegenerative disorder. This suggests that NID2 may be a potential target for neurodegenerative disorder therapies that target RNA molecules involved in the development and progression of these disorders.

Furthermore, NID2 has also been shown to be involved in infertility. Studies have shown that NID2 was expressed in the testes of individuals with infertility and that it was associated with low sperm count and poor sperm motility. This suggests that NID2 may be a potential target for therapies aimed at improving fertility in individuals with infertility.

In conclusion, NID2 is a novel gene expressed in the human placenta that has been shown to play a critical role in various physiological processes in the body. The results of in vitro and in vivo studies suggest that NID2 may be a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and infertility. Further research is needed to fully understand the functions of NID2 and to develop effective therapies that target it.

Protein Name: Nidogen 2

Functions: Cell adhesion glycoprotein which is widely distributed in basement membranes. Binds to collagens I and IV, to perlecan and to laminin 1. Does not bind fibulins. It probably has a role in cell-extracellular matrix interactions

The "NID2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NID2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets